$0.39
+0.00 (+0.78%)
Open$0.41
Previous Close$0.39
Day High$0.41
Day Low$0.38
52W High$74.30
52W Low—
Volume—
Avg Volume959.6K
Market Cap270.2K
P/E Ratio—
EPS$-74.04
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+835.9% upside
Current
$0.39
$0.39
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.01M | 335.8K | 347.3K |
| Net Income | -51,846,913 | 43.0K | 52.4K |
| Profit Margin | -1,721.0% | 12.8% | 15.1% |
| EBITDA | -40,810,202 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | — | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |